Lindsay Fourman, MD, is an endocrinologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School

METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy

Baseline data from METRE-PL, the first placebo-controlled clinical study to evaluate the therapeutic efficacy and safety of metreleptin in familial partial lipodystrophy (FPLD), identified a substantial metabolic disease burden in this patient population, including diabetes and hypertriglyceridemia, despite extensive use of antidiabetic and lipid-lowering therapies.

These data were presented at the Endocrine Society (ENDO) Annual Meeting 2026, with the ongoing global trial evaluating change from baseline in HbA1c and percent change in triglycerides (TG) at Month 6 in those with baseline HbA1c ≥7% and baseline TG ≥500 mg/dL, respectively. Safety is being assessed throughout the 12-month treatment period and during post-treatment follow-up.

Senior author and primary investigator Lindsay Fourman, MD, endocrinologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, spoke with 

 about the unmet need and multisystem metabolic dysfunction experienced by patients with FPLD.

“We've already tried all the usual conventional medications, and most patients are on multiple medications to treat diabetes and lipids prior to getting into the study, and despite this, like optimal medical therapy that we've tried, they still have such poorly controlled disease,” Fourman said.

Lipodystrophies constitute a group of rare, heterogeneous disorders characterized by partial or generalized deficiency of adipose tissue, while FPLD is a form of congenital lipodystrophy. The disease prevalence of FPLD has been estimated at around 1 in 100,000. Accumulating evidence in recent years has shown that a patient’s phenotype is not merely dependent on a specific genetic mutation, but is also defined by a combination of demographic (age, sex), environmental, and genetic factors.

Metreleptin is a recombinant analog of the human hormone leptin, functioning as replacement therapy in patients with leptin deficiency. By binding to leptin receptors in the hypothalamus, it mimics natural leptin signaling, which helps regulate appetite, restore energy balance, and improve metabolic processing of glucose and lipids.

In conditions like lipodystrophy, severe leptin deficiency leads to ectopic fat storage (lipotoxicity), insulin resistance, and hypertriglyceridemia. Metreleptin may reverse these metabolic complications by increasing insulin sensitivity, lowering HbA1c levels, and reducing circulating triglycerides.

The US Food and Drug Administration (FDA) approved metreleptin, alongside diet, for the treatment of metabolic complications of leptin deficiency in generalized lipodystrophy, but not partial lipodystrophy (PL). FPLD, a genetic form of PL, therefore does not have an FDA-approved therapy.

“While there is some data that it does help in these populations, there's never been a randomized study to demonstrate that, and so this is an important stepping stone towards demonstrating efficacy and safety, and potentially changing the way that we treat partial lipodystrophy,” said Fourman.

Fourman and colleagues are conducting the 12-month, randomized, multicenter, double-blind, placebo-controlled phase 3 study, with patients from 22 sites across 7 countries, randomized in a 1:1 ratio to receive metreleptin (maximum dose, 10 mg/day) or placebo.

METRE-PL includes 69 patients ≥12 years of age with an established diagnosis of FPLD and metabolic abnormalities (HbA1c ≥7% and/or fasting triglycerides (TG) ≥500 mg/dL) despite optimized and stable medical treatment. Key exclusion criteria included prior metreleptin treatment, leptin levels >20 ng/mL, acquired partial lipodystrophy, and HIV-associated lipodystrophy.

At baseline, 93% of patients had diabetes and 83% had hypertriglyceridemia. Pancreatitis and diabetic neuropathy each affected 29% of patients and were identified as the most common end-organ complications.

Among patients, mean HbA1c was 8.6% (±1.53; 4.9–12.9), and mean triglycerides were 696 mg/dL (±1001.1; 81–5487). Median leptin value was 8.3 ng/mL. In total, 96% of patients were taking ≥1 antidiabetic therapy and 91% were taking ≥1 lipid-lowering therapy.

Fourman told HCPLive that METRE-PL has just finished enrolling and that the final participant will complete the study this summer, with data expected in the fall.

Editor’s Note: Fourman reports relevant disclosures with Theratechnologies, Chiesi Farmaceutici, and Rhythm Pharmaceuticals.

Oral EA, Fourman LT, Montenegro RM Jr, et al. A 12-month randomized, multicenter, double-blind, placebo-controlled phase 3 study to evaluate the safety and efficacy of metreleptin in subjects with partial lipodystrophy: the METRE-PL study. Presented at: Endocrine Society Annual Meeting (ENDO 2026); June 14, 2026.

PubChem. Metreleptin. Nih.gov. Published 2026. Accessed June 24, 2026. 

https://pubchem.ncbi.nlm.nih.gov/compound/Metreleptin

Aikaterini Kountouri, Emmanouil Korakas, Eirini Maratou, et al. Familial Partial Lipodystrophy: Clinical Features, Genetics and Treatment in a Greek Referral Center. 

International Journal of Molecular Sciences

Videos

First placebo-controlled phase 3 METRE-PL data show prevalent metabolic burden in familial partial lipodystrophy (FPLD) despite standard therapy.


Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

In this episode titled “Distinguishing CSU From Chronic Inducible Urticaria Subtypes,” the panel looks at how CSU differs from chronic inducible urticaria (CIndU) and its subtypes. The panelist explains that inducible urticarias have an identifiable physical trigger, the most common being dermatographism, in which scratching, tight clothing, or waistbands provoke hives at the site of pressure. Cold-induced urticaria is another recognizable subtype, often described by patients as hives that appear after re-warming following cold exposure, such as a child breaking out after a chilly soccer practice.

Distinguishing CSU From Chronic Inducible Urticaria Subtypes

The panelist stresses that many CSU patients also report a component of dermatographism or other inducible triggers, but this does not change the underlying diagnosis: a patient only qualifies as having a true inducible urticaria if hives occur exclusively with the trigger and never spontaneously. Misclassifying these patients as having an inducible urticaria rather than CSU is a meaningful error, since it unnecessarily limits available treatment options. Published data suggest 10% to 30% of CSU patients also experience concomitant inducible urticaria, meaning clinicians must carefully tease out whether hives ever occur without a trigger before assigning a diagnosis.

The panel agrees that accurately identifying the spontaneous component of a patient’s urticaria, rather than focusing solely on apparent triggers, is essential for ensuring patients are not steered away from the more effective advanced therapies available for CSU. This distinction carries real clinical stakes, since treatment options for a true inducible urticaria remain far more limited than the advanced therapy classes now approved specifically for CSU. Taking the time to clarify whether hives ever truly occur in the absence of a trigger, rather than assuming a label based on the most obvious provoking factor, ultimately determines which treatments a patient can access. In the next episode, “A Practical Diagnostic Workup for CSU,” the panel shares a bedside approach to confirming CSU, differentiating it from urticarial vasculitis, and explaining why extensive lab and allergy testing usually adds little value.

Video Series

Oksana Hamidi, DO, is an associate professor in the division of endocrinology and metabolism at UT Southwestern Medical Center

In this episode, ‘Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes,’ the panelists explore the clinical features that should raise suspicion for underlying hypercortisolism in patients with type 2 diabetes and discuss practical approaches to screening and diagnosis in endocrinology practice. The expert faculty emphasize that many manifestations of hypercortisolism overlap with common metabolic conditions, making identification particularly challenging in this patient population. They explain how clinicians can look beyond traditional metabolic risk factors and focus on additional signs that may indicate cortisol excess.

Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes

Throughout the discussion, the panel of experts highlights the importance of recognizing catabolic features such as proximal muscle weakness, sarcopenia, osteoporosis, fragility fractures, delayed wound healing, and characteristic skin findings. They also examine neurocognitive symptoms, including depression, memory impairment, and cognitive decline, as well as cardiovascular indicators such as resistant hypertension, hypokalemia, and thromboembolic events. The faculty stress that these findings may serve as important clues when evaluating patients with difficult-to-control diabetes who do not fit the expected clinical picture.

The conversation also addresses the diagnostic evaluation of suspected hypercortisolism and reviews commonly used first-line screening tests. Panelists discuss the role of the overnight dexamethasone suppression test, late-night salivary cortisol measurements, and 24-hour urinary free cortisol collection, including practical considerations for test administration and interpretation. They emphasize the importance of proper patient preparation and awareness of factors that can influence results. By combining clinical insight with practical diagnostic guidance, the panel provides a framework for identifying patients who may benefit from further evaluation and highlights the importance of maintaining a high index of suspicion for hypercortisolism in individuals with type 2 diabetes.

The next episode in this series, ‘Interpreting Screening and Diagnostic Tests in Hypercortisolism,’ features the panelists discussing how to evaluate and interpret commonly used screening tests for hypercortisolism while accounting for potential confounding factors and false-positive results. The panel of experts also explores strategies for confirmatory testing, managing discordant findings, and applying clinical judgment throughout the diagnostic process.

Welcome back to another HCPLive Peers & Perspectives series. In this episode titled “Diagnosing the Hallmark Signs and Symptoms of CSU,” moderator Andrea Nguyen, DMSc, MPAS, PA-C, discusses chronic spontaneous urticaria (CSU) with Matthew Zirwas, MD. The episode opens with the moderator asking the panelist to describe the hallmark signs of CSU and the patient population most affected. The panelist explains that CSU is defined by spontaneously appearing hives that present as raised, red wheals surrounded by a blanched halo, can occur anywhere on the body, and typically resolve and recur unpredictably. He notes that roughly one-third of patients also develop angioedema, deep tissue swelling that commonly affects the lips, face, or hands. While CSU can occur at any age, including in children and older adults, onset is most common among women in their 20s and 30s.

Diagnosing the Hallmark Signs and Symptoms of CSU

The panelist highlights a strong association between CSU and autoimmune thyroid disease, recommending that patients have anti-thyroid peroxidase antibodies checked and, regardless of the result, undergo annual TSH monitoring for life, since elevated thyroid risk often develops over time even when initial testing is normal. He frames CSU for patients as an autoimmune condition that raises susceptibility to other autoimmune diseases, helping set expectations for long-term monitoring.

The conversation also touches on the well-documented female predominance of CSU, cited at roughly a 2-to-1 ratio in published literature, though clinical impression in practice can skew even more heavily toward women, possibly reflecting differences in care-seeking behavior between sexes. Population-based estimates, including a recent claims-data analysis, place CSU prevalence at approximately 0.78%, translating to several million affected Americans. The panel underscores that despite being common and burdensome, CSU is frequently underrecognized in clinical practice, setting the stage for a deeper discussion of diagnostic nuances ahead. In the next episode, “Distinguishing CSU From Chronic Inducible Urticaria Subtypes,” the panel explains how to tell true inducible urticarias apart from CSU with an inducible component, and why getting that distinction right protects patient access to effective therapy.

Welcome back to another HCP Live Peer Exchange series. In this episode titled, ‘Prevalence and Recognition of hypercortisolism’, expert faculty discuss the growing body of evidence highlighting the prevalence of hypercortisolism in patients with type 2 diabetes (T2D) and explore why the condition may be more common than previously recognized. The panel reviews data suggesting that while overt hypercortisolism may affect a small percentage of patients with T2D, rates increase substantially when evaluating individuals with so-called hidden hypercortisolism, particularly among those with difficult-to-control diabetes despite optimized treatment.

Prevalence and Recognition of Hypercortisolism

Throughout the discussion, the panel of experts examines recent findings demonstrating abnormal dexamethasone suppression test responses in patients with poorly controlled T2D, resistant hypertension, and other metabolic complications. They explore how these observations are reshaping clinical understanding of hypercortisolism and prompting greater consideration of cortisol excess in patient populations that may not exhibit classic signs or symptoms of the disease.

The faculty also discuss which patient groups are most likely to be underrecognized in clinical practice, including individuals with refractory diabetes and resistant hypertension who continue to experience poor outcomes despite multiple therapeutic interventions. Panelists emphasize that many patients with hypercortisolism do not present with the traditional cushingoid features commonly described in medical training, making recognition particularly challenging.

By examining evolving prevalence data and discussing real-world clinical experience, the panel highlights the importance of looking beyond traditional phenotypic presentations to identify patients who may benefit from further evaluation for hypercortisolism. The discussion underscores the need for heightened awareness and consideration of cortisol excess in patients with difficult-to-manage metabolic disease.

In the next episode, ‘Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes’, panelists will continue their discussion on hypercortisolism and highlight the clinical features that may raise suspicion for cortisol excess in patients with type 2 diabetes. The panel of experts will also review common screening and diagnostic approaches used in endocrinology practice and discuss practical considerations for identifying patients who may benefit from further evaluation.

Umayr Shaikh, MPH, is an MD candidate as of June 2026, a medical student at Georgetown University School of Medicine, and a research fellow in dermatology.

Podcasts

In the latest Skin of Color Savvy episode, Umayr Shaikh, MPH, shares how his work is shaping his medical career.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Skin of Color Savvy—A New Generation of Dermatology Leadership, With Umayr Shaikh, MPH

John Sonnenberg, PhD, clinical psychologist, founder of Uptown Research Institute, and faculty at Northwestern University Feinberg School of Medicine.

John Sonnenberg, PhD, reflects on Emerge Phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

This episode covers the recent trial of the Signos weight loss platform, indicating weight loss that could challenge GLP-1 receptor agonists.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Signos and the Science of Weight Loss

Zobair Younossi, MD, MPH, is chairman of the Global NASH/MASH Council and professor and chairman of Beatty Liver and Obesity Research at Inova Health System.

Zobair Younossi, MD, explains how lifestyle, drugs, and EXCEL data show steatosis and fatigue improvements in MASLD.


Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Lifestyle, Pharmacologic Therapies, and EXCEL Trial Data Reshape MASLD Treatment Framework

Lisa Horne, director of marketing at the Food Allergy & Anaphylaxis Connection Team (FAACT).

A new 4-part microdrama series developed with real young adults living with food allergies aims to bridge the gap between clinical management and everyday life.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

FAACT's “Food Allergies in the City” Offers Clinicians a Window into Patients' Daily Life 

Elaine Siegfried, MD, is a professor of Pediatrics and Dermatology at the Saint Louis University School of Medicine and is the director of Pediatric Dermatology at SSM Health Cardinal Glennon Children's Hospital in St. Louis, Missouri.

Articles

Siegfried discusses some of the most notable highlights of her session at the RAD 2026 conference regarding clinical pearls in dermatology.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Key Clinical Practice Pearls in Atopic Dermatitis, With Elaine Siegfried, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Corxel reported CX11 met phase 2 endpoints in adults with obesity or overweight, with up to 11.5% weight loss at 36 weeks.

CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports

Learn how clinicians spot uncommon diabetes causes—from pancreatic disease and MODY to steroids, transplants, and checkpoint inhibitors—before treatment.

From Label to Etiology: Applying the 2026 AACE Framework

Explore signs of uncommon diabetes—from pancreatic disease and MODY to steroid, transplant, and checkpoint-inhibitor autoimmune causes.

How the 2026 AACE Algorithm Broadens the Lens on Diabetes

Aboul-Fettouh recounts a case in which an incidental skin examination revealed longstanding, undertreated AA in a patient who had been told no effective therapy existed, illustrating how the new generation of JAK inhibitors can restore both hair and hope.

Latest News

METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy

Distinguishing CSU From Chronic Inducible Urticaria Subtypes

Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes

Diagnosing the Hallmark Signs and Symptoms of CSU

Prevalence and Recognition of Hypercortisolism